Detalles de la búsqueda
1.
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.
Int J Gynecol Cancer
; 2024 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38724236
2.
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Int J Gynecol Cancer
; 33(8): 1253-1259, 2023 08 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37072323
3.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(7): 919-930, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35690073
4.
The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
Br J Cancer
; 126(6): 851-864, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716396
5.
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
Br J Cancer
; 127(1): 92-101, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35568736
6.
BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
Br J Cancer
; 127(1): 163-167, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35260807
7.
c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial.
BMC Med
; 20(1): 59, 2022 02 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35144591
8.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol
; 167(3): 404-413, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36273926
9.
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 277-288, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33357510
10.
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Gynecol Oncol
; 163(1): 72-78, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34412908
11.
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Int J Gynecol Cancer
; 31(7): 949-958, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34103386
12.
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.
Lancet Oncol
; 21(7): 969-977, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32615110
13.
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(5): 710-722, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32359490
14.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Lancet
; 394(10214): 2084-2095, 2019 12 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31791688
15.
Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Gynecol Oncol
; 156(3): 545-551, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31932108
16.
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Gynecol Oncol
; 159(1): 101-111, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32861537
17.
First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
Curr Oncol Rep
; 22(6): 64, 2020 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32494876
18.
Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases.
J Med Genet
; 56(5): 301-307, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30683677
19.
Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer.
Int J Gynecol Cancer
; 29(2): 341-345, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30674568
20.
Palliative home parenteral nutrition in patients with ovarian cancer and malignant bowel obstruction: experiences of women and family caregivers.
BMC Palliat Care
; 18(1): 120, 2019 Dec 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31884962